Thrombin is classically recognised as factor IIa of the coagulation cascade, where it catalyses the conversion of fibrinogen into fibrin and so aids in the formation of a blood clot. Active thrombin is generated from prothrombin at the cell surface of platelets, lymphocytes, monocytes, neutrophils and endothelial cells.' It belongs to the serine protease enzyme group, members of which share a common catalytic mechanism and also the triad of amino acids at their active site (aspartate-serine-histidine) from which their name derives. Thrombin has several forms, the largest and most active of which is 39 kD ct-thrombin. It is able to catalyse the cleavage of a wide range ofproteins including itself.
Recently it has been found that thrombin causes a number of pro-inflammatory and mitogenic effects, many of which appear to take place after thrombin cleavage of a G-protein coupled transmembrane receptor. These in vitro observations suggest that thrombin may be important in the healing process, acting as a mediator of inflammation and initiating repair through the stimulation of cell growth. It has also been linked with the development of vascular disease, notably atherosclerosis.2 However, the multiple actions of thrombin implicate this enzyme in the pathogenesis of any disorder where there is sustained vascular injury and cellular infiltration.
In particular thrombin may be important during the progression of rheumatoid arthritis (RA), a chronic inflammatory disease marked by increased vascular permeability, synovial proliferation, and an abnormal angiogenic response. Extravascular coagulation is also seen in RA, with fibrin deposition being a well documented feature of inflamed synovial tissue. Advances in immunohistochemical techniques have made it possible to demonstrate the existence of intact coagulation pathways within the rheumatoid synovium. 34 This review describes current knowledge about how thrombin works to promote successful healing, and outlines the pathological relevance of prolonged and inappropriate thrombin activity in RA. 
ENDOGENOUS THROMBIN INHIBITORS
Uncontrolled thrombin action is prevented by members of the serine protease inhibitor (serpin) superfamily,9 which embraces a large number of regulatory plasma proteins such as plasminogen activator inhibitor-I (PAI-1) and ot2-antiplasmin. Serpins display sequence homology and share common structural features, forming stable 1:1 complexes with serine protease enzymes. They possess a reactive centre as part of an external polypeptide loop, and within this reactive centre is a bond that can be cleaved by the target enzyme. Particular serpins tend to be more efficient as inhibitors of certain serine proteases, but none are entirely specific.
Antithrombin III (AT-III) is the main circulating inhibitor of thrombin, although other serpins may also contribute. It complexes with thrombin through its reactive arginineserine bond,'01' and can also inhibit Factors IXa, Xa, XIa and XIIa. However, thrombin appears able to bind to the subendothelial extracellular matrix without loss of function and, once bound, is protected from inhibition by plasma AT-III.12 It is therefore not surprising to find a second serpin, protease nexin-1 (PN-1), that directly controls thrombin action at the cell surface. PN-1 is secreted by many cell types in vitro including human and mouse fibroblasts'3 '4 and bovine Inactivation of serpins in inflamed tissues Serpins are susceptible to inactivation during the inflammatory process, owing to the exposed location of their reactive centre on the outside of the molecule. Reactive oxygen species from neutrophils readily oxidise a critical methionine residue, present in the reactive centre of several serpins, for example, oxl-antitrypsin (ox,-AT;25). Moreover the presence of inflammatory mediators such as interleukin-1 (IL-1) stimulates the release of various cell-derived protease enzymes.26 Neutrophils produce elastase, a serine protease, and connective tissue cells secrete metalloproteinases including collagenase and the stromelysins. These enzymes degrade joint tissues. They can also inactivate serpins by proteolysis within the exposed loop region, and so may disturb the delicate balance between thrombin and its inhibitors.
Such an event has already been demonstrated for neutrophil elastase, whose associated serpin, ot,-AT, can be cleaved by stromelysin.27 28 The proportion of cleaved ol-AT in RA synovial fluid is higher than in osteoarthritic synovial fluid or normal serum,29 and consequently RA synovial fluid has a reduced capacity for elastase inhibition.30
Elastase itself will cleave both AT-III and PN-1 in vitro, and after cleavage these serpins are no longer effective as thrombin inhibitors.3' " Thrombin in inflammation and healing
THROMBIN AS A MEDIATOR OF INFLAMMATION
As might be expected of a coagulative enzyme, thrombin acts directly to cause platelet aggregation34 and potentiate coagulation. As well as activating Factor V35 and stimulating release of factor VIII from the endothelium,36 it increases the production of tissue plasminogen activator37 and PAI-138 by endothelial cells.
Thrombin also contributes to the inflammatory process by upregulating arachidonic acid synthesis. This in turn leads to the release by endothelial cells39 of prostacyclin (PGI2), a powerful vasodilator and, paradoxically, an inhibitor of platelet aggregation. In addition, thrombin enhances production of platelet activating factor,40 which is a potent mediator of inflammatory changes including vasodilatation, increased vascular permeability, and monocyte chemotaxis. A direct effect on vessel permeability takes place through thrombininduced contraction of endothelial cells.4' This contraction results in the formation of intercellular gaps, and increased endothelial permeability to fluid and macromolecules. 42 Adherence of polymorphonuclear leukocytes (PMN) to the vessel wall and their subsequent migration into tissues are important factors in the early stage of inflammation. Thrombin promotes these events in two ways. It is a chemoattractant for PMN43 and increases their adhesion to the endothelial surface.44 4
Thrombin also exhibits similar chemotactic and adhesion-stimulating properties for the monocytes seen later in the inflammatory response.46 47 It appears that thrombin can upregulate expression of the adhesive proteins P-selectin and intercellular adhesion molecule-1 (ICAM-1) on the endothelial cell membrane, where the enzyme may act both alone and also synergistically with the cytokines IL-1 and tumour necrosis factor-ox (TNF-ot; 48 49) . P-selectin itselfhas recently been shown to play a major role during monocyte adhesion to the rheumatoid synovial vasculature.50
MITOGENICITY AND HEALING
The importance of platelet derived growth factors (PDGF), the fibroblast growth factors (FGF), and epidermal growth factor in proliferation and healing has been recognised for many years. Like these well-known mitogens, thrombin stimulates proliferation in fibroblastic and other cell types, with the response occurring at low concentrations of the enzyme. In vitro thrombin has been shown to be mitogenic for fibroblasts, lymphocytes, endothelial cells, vascular smooth muscle cells and monocytes.1-'5 This mitogenesis can be stimulated by low levels of active thrombin, and we have observed thrombin-stimulated proliferation of murine 3T3 fibroblasts in the presence of only five NIH units of thrombin activity/ml culture medium. Fibroblasts are able to regulate such thrombin-induced proliferation by releasing the thrombin inhibitor PN-1 in a dose-dependent manner during thrombin stimulation. 56 Thrombin also has an indirect effect on cellular growth. It causes the release of PDGF,57 and acts together with basic FGF in stimulating proliferation of vascular smooth muscle cells.58 Thrombin may therefore work with other growth factors in initiating the healing of inflamed tissues through proliferation and angiogenesis. Full dermal incisions in normal rats receiving a single topical application of thrombin showed accelerated healing and neovascularisation in the treated wounds. 59 The mitogenic effects of thrombin may also be important in the cellular proliferation seen in RA (see below).
The neural effects of thrombin Thrombin acts as a mitogen for astrocytes,60 non-neuronal supportive cells of the brain, but in contrast appears to inhibit the growth of neurons. In vitro it has been found to block neurite outgrowth from chick sympathetic ganglia and embryonic mouse spinal cord neurons.6' 62 Thrombin is also able to reverse neurite outgrowth from neuroblastoma cells that have been induced to extend neurites by serum removal. 63 The location of prothrombin messenger RNA transcripts in rat and human cerebral cortex and cerebellum, as well as in neural cell lines, suggests that thrombin may be involved normally in development and function of the nervous system."
The thrombin inhibitor PN-1 is abundant in and around the walls of human cerebral blood vessels. 65 Here it may protect against the damaging effects of excess thrombin, which could leak from the vasculature into brain tissues as a consequence of injury or inflammation. It has been found that crushing rat peripheral nerves causes a seven-fold increase in the release of PN-1,66 where maximum upregulation correlated with the appearance of macrophages in the tissue rather than the actul time of injury. IL-1, TNF-a, and transforming growth factor-n have also been shown to increase PN-1 production by neural cells, the greatest effect being produced by IL-1"67 However, a defensive mechanism based around PN-1 might be unable to maintain its integrity where there is widespread enzymatic inactivation of serpins, as is thought to take place during chronic inflammatory disease. The relevance of this observation to the proposed neural component of RA will be discussed in a later section.
Mechanism of thrombin action
During studies on the non-coagulative actions of thrombin it was found that mitogenesis and neurite retraction could not be reproduced when catalytically inactive forms of the enzyme were used.5' 63 68 Although modified thrombins and partial thrombin sequences bound to the thrombin receptor, they failed to elicit a cellular response.55 69 70 This suggested that these actions of thrombin were dependent on its proteolytic activity, rather than being a simple binding interaction between enzyme and receptor as seen with many other ligands, for example, acetylcholine.
ACTIVATION OF THE THROMBIN RECEPTOR
To clarify the mechanism of receptor activation, Vu et al cloned the human thrombin receptor, finding it to be a member of the seven transmembrane domain receptor family.7' These G-protein coupled receptors possess sequence similarities and share certain structural characteristics, particularly in the transmembrane regions. A large number of molecules work through such receptors, and differing activation mechanisms within the receptor family probably reflect the wide variety of ligands served. Thrombin, however, does not act by any of the previously described mechanisms. Instead the proposed model involves thrombin cleavage of an arginineserine bond within the receptor's extracellular N-terminal region, creating a new N-terminus which is itself the ligand for receptor activation.7' Current work is directed towards characterising the exact binding site of this 'tethered' ligand. It is likely that a similar or identical thrombin receptor is present on nonplatelet cells, since peptide agonists comprising the final 14 amino acids of the new N-terminus are able to mimic the effects of thrombin on fibroblasts and other cell types in uitro.54 55 72 73 CELLTLAR SIGNALLING PATHWAYS Three phospholipases are known to be stimulated after binding at the thrombin receptor. Activation of phospholipase C72 74 75 leads to hydrolysis of phosphatidyl inositol 4,5-bisphosphate (PIP2) and release of its breakdown products, inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 causes calcium to be liberated from intracellular stores, and this accounts for much of the rapid and sustained increase in cytosolic calcium seen after thrombin exposure of numerous cell types. 73 Calcium is able to bring about complex alterations in cytoskeletal components, including microtubule disassembly80 and activation of actin-depolymerising proteins.8' Raised calcium levels may therefore be linked with the morphological changes evoked by thrombin, such as endothelial cell contraction and neurite retraction.
The other product of PIP2 hydrolysis, DAG, is an activator of protein kinase C (PKC), and thrombin-stimulated cellular events can be blocked if PKC is first desensitised by treating the cells with phorbol esters. 79 These synovia were removed at joint replacement surgery from patients with longstanding disease, and thus it seems likely that proliferation occurs much earlier on in the disease process. Importantly, the joint erosions associated with synovial overgrowth have been found to develop within two years of RA onset.86
REDUCED SYNOVIAL INNERVATION
Another potentially pathogenic change is seen in the innervation of the rheumatoid synovium. Normal synovium is well innervated by small diameter nerve fibres, found both perivascularly and as free fibres in the tissue, but these fibres are severely depleted in the synovial tissue of RA patients. In particular, although sympathetic innervation of deeper blood vessels matches that of normal synovium, there appear to be no sympathetic fibres around the more superficial vessels.87
Two main observations suggest that there is a neural influence in RA. First, the disease is characterised by its symmetry. Secondly, inflammation is precisely localised to the affected joints, and this is difficult to explain purely through the effects of circulating factors.
Clinical data appear to confirm the involvement of the nervous system.88 For example, twelve patients previously paralysed by poliomyelitis showed almost total sparing of the paralysed limbs after the onset of RA. 89 The 'axon reflex' theory suggests that small diameter nociceptive fibres are stimulated in inflammatory mediators in the inflamed joint. Impulses pass up through the spinal cord to higher centres, but are also propagated in reverse through the other branches of the nerves.90 Pro-inflammatory peptides are then thought to be released by the terminals of these fibres, exacerbating inflammation 
